HC Wainwright Forecasts Reduced Earnings for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – Equities research analysts at HC Wainwright dropped their Q2 2027 earnings estimates for Delcath Systems in a research report issued on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.11 per share for the quarter, down from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Delcath Systems’ FY2028 earnings at $0.68 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.61 EPS.

Several other equities analysts have also recently commented on DCTH. Weiss Ratings cut shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Zacks Research lowered Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, BTIG Research upped their price objective on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.33.

Delcath Systems Stock Performance

DCTH opened at $20.10 on Wednesday. The company has a 50-day moving average of $15.60 and a 200-day moving average of $12.54. The company has a market capitalization of $697.47 million, a P/E ratio of 125.62 and a beta of 0.62. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $21.84.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a net margin of 6.05% and a return on equity of 5.78%. The firm had revenue of $35.10 million for the quarter, compared to the consensus estimate of $25.99 million.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently bought and sold shares of DCTH. Bank of New York Mellon Corp bought a new position in Delcath Systems in the second quarter worth about $1,362,000. Allspring Global Investments Holdings LLC bought a new position in shares of Delcath Systems during the first quarter valued at approximately $306,000. Kopp Family Office LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $450,000. Sei Investments Co. raised its position in shares of Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after purchasing an additional 22,029 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Delcath Systems by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares during the period. Institutional investors and hedge funds own 61.12% of the company’s stock.

Trending Headlines about Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analysts’ consensus estimate of a $0.09 loss, and revenue of $35.1 million, well above the $26.0 million expected. The company also raised its 2026 revenue outlook to $115 million–$117 million, compared with consensus of $106.2 million. Earnings report
• Positive Sentiment: HC Wainwright reiterated its Buy rating and lifted its price target from $32 to $36. It also raised its EPS forecasts for 2028, 2029 and 2030 to $0.68, $1.08 and $1.61, respectively. The stock recently reached a new 12-month high following the earnings news. Delcath reaches a 12-month high
• Negative Sentiment: HC Wainwright lowered its Q2 2027 EPS estimate slightly, to $0.11 from $0.12. This modest near-term reduction contrasts with its higher longer-term forecasts. HC Wainwright research

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.